Evidence map›Paper›PMID 39738219›Full record

ArticleNPJ vaccines2024

Immunogenicity and safety of the 15-valent pneumococcal conjugate vaccine, a systematic review and meta-analysis.

Gernot Wagner, Gerald Gartlehner, Kylie Thaler, Dominic Ledinger, Johanna Feyertag, Irma Klerings, K M Saif-Ur-Rahman, Declan Devane, Kate Olsson, Karam Adel Ali and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Capsule and PspA Cooperatively Confer Resistance ofInternational journal of molecular sciences · 2026
    Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Gernot WagnerDepartment for Evidence-based Medicine and Evaluation, University for Continuing Education Krems (Danube University Krems), Krems, Austria. gernot.wagner@donau-uni.ac.at.ORCID http://orcid.org/0000-0003-3626-3403
Gerald GartlehnerDepartment for Evidence-based Medicine and Evaluation, University for Continuing Education Krems (Danube University Krems), Krems, Austria.
Kylie ThalerDepartment for Evidence-based Medicine and Evaluation, University for Continuing Education Krems (Danube University Krems), Krems, Austria.
Dominic LedingerDepartment for Evidence-based Medicine and Evaluation, University for Continuing Education Krems (Danube University Krems), Krems, Austria.
Johanna FeyertagDepartment for Evidence-based Medicine and Evaluation, University for Continuing Education Krems (Danube University Krems), Krems, Austria.
Irma KleringsDepartment for Evidence-based Medicine and Evaluation, University for Continuing Education Krems (Danube University Krems), Krems, Austria.
K M Saif-Ur-RahmanEvidence Synthesis Ireland and Cochrane Ireland, University of Galway, Galway, Ireland.ORCID http://orcid.org/0000-0001-8702-7094
Declan DevaneEvidence Synthesis Ireland and Cochrane Ireland, University of Galway, Galway, Ireland.
Kate OlssonEuropean Centre for Disease Prevention and Control, Solna, Sweden.
Karam Adel AliEuropean Centre for Disease Prevention and Control, Solna, Sweden.
Sabine Vygen-BonnetImmunisation Unit, Robert Koch Institute, Berlin, Germany.
Heini SaloInfectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare (THL), Helsinki, Finland.
Dace ZavadskaDepartment of Paediatrics, Children Clinical University Hospital, Rīgas Stradiņa Universitāte, Riga, Latvia.
Marta Grgič VitekCommunicable Diseases Centre, National Institute of Public Health, Ljubljana, Slovenia.
Marje OonaInstitute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.
Robert CunneyClinical Microbiology, Children's Health Ireland at Temple Street, Dublin, Ireland.
David TuerlinckxPediatric Department, Centre Hospitalier Universitaire (CHU) Dinant Godinne UCL Namur, Yvoir, Belgium.
Frederikke Kristensen LomholtDepartment of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.
Isolde SommerDepartment for Evidence-based Medicine and Evaluation, University for Continuing Education Krems (Danube University Krems), Krems, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pneumococcal infections are a serious health issue associated with increased morbidity and mortality. This systematic review evaluated the efficacy, effectiveness, immunogenicity, and safety of the pneumococcal conjugate vaccine (PCV)15 compared to other pneumococcal vaccines or no vaccination in children and adults. We identified 20 randomized controlled trials (RCTs). A meta-analysis of six RCTs in infants showed that PCV15 was non-inferior compared with PCV13 for 12 shared serotypes. Based on a meta-analysis of seven RCTs in adults, PCV15 was non-inferior to PCV13 for 13 shared serotypes. For the unique PCV15 serotypes, 22F and 33F, immune responses were higher in infants and adults vaccinated with PCV15 compared to those receiving PCV13. Regarding safety, meta-analyses indicated comparable risks of adverse events between PCV15 and PCV13 in infants. Adults receiving PCV15 had a slightly higher risk of adverse events, though serious events were similar between groups.

Identifiers

PMID39738219
PMCPMC11685527

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.